Europe is still the most powerful international player in global health. But in an increasingly multipolar world, where differences between the developing and developed health worlds are dissolving, the way we look at global health is outdated, writes Johanna Ralston.
Putting more than 10 years of paralysis behind it, the European Commission finally launched a revision of the directive on the prevention of occupational cancers in May 2016. Lawmakers can now address reprotoxic substances in the workplace, writes Laurent Vogel.
As safety watchdogs battle over just how toxic and dangerous Monsanto’s controversial weed-killer glyphosate actually is, the even more toxic half-brother from Bayer, glufosinate, is making a timely return, warns Mute Schimpf.
Unless the European Commission changes its attitude, the innovation gap between Europe and the US will likely increase, and it could be overtaken soon by China, with dire consequences for living standards, warns Philip Stevens.
Bacteria are becoming more resistant and only a few new types of antibiotic have been introduced in recent decades. Humanity could once again suffer millions of deaths each year from infectious diseases, warn Lars Adaktusson and Magnus Oscarsson.
We are halfway through this European Parliament’s mandate and, as ever, many laws have been voted, with many more to come. But will they be effectively introduced at the national level in the area of health? Denis Horgan asks.
Lung cancer is the leading cause of cancer death in the EU and 267,700 people die from it each year across Europe. MEPs and cancer activists call for more to be done to tackle the burden of this disease on the individuals diagnosed, their families and our society.
The EU’s antitrust case against Google should be widened to cover the local search market. Lack of competition in this domain harms consumers, EU companies and the Digital Single Market, writes Kostas Rossoglou.